Limits...
Liposomal delivery systems for intestinal lymphatic drug transport

View Article: PubMed Central - PubMed

ABSTRACT

Intestinal lymphatic drug delivery has been widely studied because drugs can bypass the first-pass metabolism in the liver via the lymphatic route, which increases oral bioavailability. Various lipid-based nanoparticles have been used to deliver hydrophobic drugs to the lymphatic pathway. This review focuses on the liposomal delivery systems used for intestinal lymphatic drug transport. Liposomal formulations have attracted particular attention because they can stimulate the production of chylomicrons and the incorporated drugs readily associate with enterocyte-derived chylomicrons, enhancing lymphatic drug transport. We believe that a full understanding of their contribution to intestinal drug translocation will lead to effective oral delivery with liposomal formulations.

No MeSH data available.


Liposomes with a hydrophilic drug a encapsulated in the aqueous core and a hydrophobic drug b incorporated into the membrane
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5120490&req=5

Fig5: Liposomes with a hydrophilic drug a encapsulated in the aqueous core and a hydrophobic drug b incorporated into the membrane

Mentions: Liposomes are spherical vesicles formed by one or several kinds of lipid with an aqueous phase inside and between the lipid bilayers [21–23]. Hydrophilic molecules can be loaded into the interior of liposomes, and hydrophobic or lipophilic molecules into the lipid bilayer (Fig. 5). Compared with other lipid-based nanoparticles, liposomes have the ability to encapsulate and protect drugs and to increase their absorption into enterocytes. Liposomes can protect labile drugs from denaturation by the harsh conditions in the GI tract. Lipids of liposomes can also be utilized to stimulate the production of chylomicrons in enterocytes, thus enhancing drug transport into the lymphatic system. Furthermore, enterocyte uptake of liposomes can be controlled with their size; smaller showed higher uptake [24]. Therefore, this section mainly focuses on liposomal formulations for oral drug delivery, especially lymphatic drug transport.Fig. 5


Liposomal delivery systems for intestinal lymphatic drug transport
Liposomes with a hydrophilic drug a encapsulated in the aqueous core and a hydrophobic drug b incorporated into the membrane
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5120490&req=5

Fig5: Liposomes with a hydrophilic drug a encapsulated in the aqueous core and a hydrophobic drug b incorporated into the membrane
Mentions: Liposomes are spherical vesicles formed by one or several kinds of lipid with an aqueous phase inside and between the lipid bilayers [21–23]. Hydrophilic molecules can be loaded into the interior of liposomes, and hydrophobic or lipophilic molecules into the lipid bilayer (Fig. 5). Compared with other lipid-based nanoparticles, liposomes have the ability to encapsulate and protect drugs and to increase their absorption into enterocytes. Liposomes can protect labile drugs from denaturation by the harsh conditions in the GI tract. Lipids of liposomes can also be utilized to stimulate the production of chylomicrons in enterocytes, thus enhancing drug transport into the lymphatic system. Furthermore, enterocyte uptake of liposomes can be controlled with their size; smaller showed higher uptake [24]. Therefore, this section mainly focuses on liposomal formulations for oral drug delivery, especially lymphatic drug transport.Fig. 5

View Article: PubMed Central - PubMed

ABSTRACT

Intestinal lymphatic drug delivery has been widely studied because drugs can bypass the first-pass metabolism in the liver via the lymphatic route, which increases oral bioavailability. Various lipid-based nanoparticles have been used to deliver hydrophobic drugs to the lymphatic pathway. This review focuses on the liposomal delivery systems used for intestinal lymphatic drug transport. Liposomal formulations have attracted particular attention because they can stimulate the production of chylomicrons and the incorporated drugs readily associate with enterocyte-derived chylomicrons, enhancing lymphatic drug transport. We believe that a full understanding of their contribution to intestinal drug translocation will lead to effective oral delivery with liposomal formulations.

No MeSH data available.